![Bacterial diseases / Pneumonia / Antibiotics / Infectious diseases / Antimicrobial resistance / Pharmaceuticals policy / Pneumococcal pneumonia / Infection / Omadacycline / Pneumococcal infection Bacterial diseases / Pneumonia / Antibiotics / Infectious diseases / Antimicrobial resistance / Pharmaceuticals policy / Pneumococcal pneumonia / Infection / Omadacycline / Pneumococcal infection](https://www.pdfsearch.io/img/f709d86e4ec4c8bdc94ba5c1c7c29fe7.jpg) Date: 2016-01-12 07:22:29Bacterial diseases Pneumonia Antibiotics Infectious diseases Antimicrobial resistance Pharmaceuticals policy Pneumococcal pneumonia Infection Omadacycline Pneumococcal infection | | Combioxin receives Clinical Trial Authorization to initiate a first-in-man study with CAL02 in patients with severe pneumococcal pneumonia GENEVA, SWITZERLAND, 12 January 2016 – Combioxin SA is pleased to announce thatAdd to Reading ListSource URL: www.lascco.comDownload Document from Source Website File Size: 92,33 KBShare Document on Facebook
|